Seegene Introduces World's First Fully Automated PCR Testing System at ADLM 2025

Seegene's Groundbreaking Reveal at ADLM 2025

At the forefront of molecular diagnostics, Seegene Inc. has made waves with the announcement of its fully automated PCR testing system, CURECA™, to be unveiled at the Association for Diagnostics Laboratory Medicine (ADLM) 2025 in Chicago from July 28 to 31. Positioned to redefine diagnostic protocols, CURECA™ eliminates the need for human intervention in the entire PCR testing process, setting the stage for unparalleled efficiency and accuracy in laboratories globally.

A New Era of Automation

CURECA™ represents the world’s first complete automation of PCR testing, integrating processes from specimen storage to result analysis. This state-of-the-art system includes three essential modules: a prep module for pre-analytical processing, a diagnostic module for assay execution, and a software module for data analysis. The innovative system is not only designed for seamless 24/7 operation but also significantly minimizes the potential for human error, enhancing the reliability of test results.

One of the standout features is its automated prep module, which successfully addresses one of the most challenging stages in laboratory workflows: pre-treatment. Often repeated manually by lab technicians, this phase is renowned for being tedious and prone to inconsistencies, especially when diverse sample types such as blood, urine, and stool are involved. Historically, stool samples have been particularly difficult to automate due to their unique characteristics, creating significant operational barriers in diagnostics. However, CURECA™ breaks the mold by fully automating the pre-treatment process across all major specimen types, overcoming long-standing challenges and shifting the responsibilities of laboratory personnel from manual tasks to more strategic roles focused on data analysis and clinical interpretation.

Beyond PCR: Expanding Diagnostic Capabilities

Notably, the prep module is versatile, finding applicability not only in PCR diagnostics but also in other areas such as clinical chemistry and immunoassays. This signifies a monumental advancement in the landscape of automation across the broader diagnostics market. With a modular architecture, laboratories can configure and deploy the system according to their unique requirements, enhancing operational efficiency and throughput.

STAgora™: Real-Time Data Analytics

In tandem with the launch of CURECA™, Seegene also introduced STAgora™, its innovative data analytics platform. Designed to collect and analyze real-time PCR diagnostic data, STAgora™ empowers healthcare providers with vital insights that can influence clinical decision-making. By collating data from hospitals globally, the platform offers comprehensive visibility into regional infection trends and patterns of co-infection. Equipped with over 40 statistical tools, STAgora™ enables healthcare practitioners to align individual patient test results with local epidemiological data, subsequently refining treatment strategies and quickening diagnosis.

A Vision for Future Collaboration

Seegene’s initiatives at ADLM 2025 extend beyond product introduction; the company seeks to foster global collaboration through technology sharing and strategic partnerships. Earlier recognition at ESCMID Global 2025, a prominent conference focusing on clinical microbiology, further attests to growing interest in CURECA™. To amplify its research, development, and manufacturing capabilities in the United States, Seegene has established local subsidiaries dedicated to enhancing access to these groundbreaking technologies.

Android Daniel Shin, Seegene's Executive Vice President: "CURECA™ and STAgora™ transcend traditional diagnostics solutions; they establish a new standard set to transform the diagnostics landscape worldwide. We are committed to leveraging our substantial technological assets to promote innovative change across the global diagnostics ecosystem."

Conclusion

As Seegene continues to lead with its groundbreaking innovations, the implications of CURECA™ and STAgora™ on the world of diagnostics are profound. These technologies promise to enhance not only laboratory efficiency but also the overall quality of patient care through timely and accurate diagnostic capabilities. The pre-commercialization phase signifies not an end but a beginning—a pivotal step towards revolutionizing health care diagnostics.

For more information on Seegene's innovations and their impact on healthcare, visit Seegene's official website.